Enterome is a clinical-stage biopharmaceutical company focused on developing breakthrough immunomodulatory drugs for the treatment of cancer and immune diseases. Their pioneering approach leverages a unique ability to decode the interaction between the gut microbiome and the immune system, using a proprietary Mimicry platform to identify novel therapeutics from a vast database of gut microbiome proteins. The company is advancing pipelines of drug candidates, including OncoMimics™ for cancer and EndoMimics™ for immune diseases.